- Conditions
- COVID-19
- Interventions
- Document delays and frequencies of inadequate blood products for emergent cases
- Other
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1681–1704
of 13,797
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension
- Interventions
- amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more
- Conditions
- Influenza
- Interventions
- MF59-eH1N1_f
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 6 Months to 35 Months
- Enrollment
- 654 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 28
- States / cities
- Bentonville, Arkansas • Fort Smith, Arkansas • Canoga Park, California + 25 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tafasitamab, Tafasitamab plus lenalidomide
- Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Anaheim, California • Duarte, California + 20 more
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- Alirocumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 1 more
- Conditions
- High Risk Cervical Cancer, Advanced Cervical Cancer
- Interventions
- ADXS11-001, Placebo
- Drug
- Lead sponsor
- Advaxis, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 41
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Duarte, California + 35 more
- Conditions
- Cardiovascular Diseases
- Interventions
- Strong Hearts Urban
- Behavioral
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Unresectable Stage III, Stage IV Melanoma
- Interventions
- Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 76 more
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, Dapagliflozin, Sitagliptin, Placebo matching with Saxagliptin, Placebo matching with Dapagliflozin, Placebo matching with Sitagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 40
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 34 more
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo for Upadacitinib, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more
- Conditions
- Graves' Disease
- Interventions
- IMVT-1402, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 53 more
- Conditions
- Superficial Bladder Cancer
- Interventions
- ADSTILADRIN
- Biological
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 34
- States / cities
- Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 29 more
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
- Interventions
- daraxonrasib
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 36 more
- Conditions
- Lung Transplantation
- Interventions
- Not listed
- Lead sponsor
- University of Alberta
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Timeline
- 2023 – 2028
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 8 more
- Conditions
- Spinal Cord Injuries
- Interventions
- Arm 1, Arm 2
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 5
- States / cities
- Tampa, Florida • St Louis, Missouri • Cleveland, Ohio + 2 more
- Conditions
- Oligometastatic Prostate Cancer (OMPC)
- Interventions
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 39
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Recurrent Pericarditis, Heart Diseases, Pericarditis
- Interventions
- KPL-387
- Drug
- Lead sponsor
- Kiniksa Pharmaceuticals International, plc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 17 more
- Conditions
- Glioma
- Interventions
- BIBW 2992, TMZ, BIBW 2992 plus TMZ
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 14 more
- Conditions
- Factor XIII Deficiency
- Interventions
- FXIII Concentrate (Human) (FXIII)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Not listed
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 25
- States / cities
- Dothan, Alabama • Oakland, California • Orange, California + 22 more
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3,323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 59 more
- Conditions
- Opioid Use Disorder
- Interventions
- Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 25
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Long Beach, California + 21 more
- Conditions
- Ornithine Transcarbamylase Deficiency
- Interventions
- ARCT-810, Placebo
- Biological · Other
- Lead sponsor
- Arcturus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- Gainesville, Florida • Minneapolis, Minnesota • New York, New York + 5 more
- Conditions
- Cervical Dystonia, Blepharospasm
- Interventions
- Xeomin®
- Biological
- Lead sponsor
- Merz North America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 688 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 70
- States / cities
- Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 60 more
- Conditions
- Advanced Solid Tumors, Relapsed/Refractory Lymphoma
- Interventions
- Alisertib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Miami, Florida • Chicago, Illinois • Ann Arbor, Michigan + 4 more